Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLT PET vs CT in Resectable NSCLC
NCT00963807Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoints: Change in 18F-Fluorothymidine (FLT) Uptake at 6 weeks and Change in FLT Uptake in Responders and Non-responders at 6 weeks. Started Sep 2009; status: completed.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00963807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00963807.